Skip to main content

Table 2 Goodness of fit and model parameters for the PFS, PrePS and PPS curves

From: Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma

 

Exponential

Weibull

Log-logistic

Log-Normal

Gamma

Gompertz

PFS VR-CAP

Intercept

7.142

7.146

6.758

6.772

7.148

3.72

Scale

N/A

1.011

0.839

1.567

1.007

N/A

Shape

N/A

N/A

N/A

N/A

1.007

−0.0001

AIC

603.623

605.604

608.385

616.888

607.603

1194.398

BIC

607.116

612.590

615.371

623.874

618.082

1201.384

PFS R-CHOP

Intercept

6.571

6.566

6.138

6.134

6.374

3.087

Scale

N/A

0.913

0.654

1.22

1.042

N/A

Shape

N/A

N/A

N/A

N/A

0.54

−0.005

AIC

634.079

634.075

622.425

636.948

630.674

1349.269

BIC

637.576

641.070

629.419

643.942

641.166

1356.263

PrePS and PPS

Intercept

7.61

6.657

7.309

7.355

7.765

4.232

PrePS VR-CAP

1.511

1.635

1.685

1.979

1.573

1.511

Pre-PS R-CHOP

1.385

1.499

1.571

1.896

1.412

1.385

Scale

N/A

1.083

0.964

1.883

1.749

N/A

Shape

N/A

N/A

N/A

N/A

1.749

0.002

AIC

915.60

916.37

920.84

929.16

917.11

1717.58

BIC

932.35

937.31

941.78

950.11

942.24

1738.52

  1. Abbreviations: AIC Aikake information criterion, BIC Bayesian information criterion, PFS progression-free survival, PPS post-progression survival, PrePS pre-progression survival, R-CHOP rituximab with cyclophosphamide, doxorubicin, vincristine and prednisolone, VR-CAP bortezomib with rituximab, cyclophosphamide, doxorubicin and prednisolone
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us